New York Institute of Technology v. Biosound, Inc.

658 F. Supp. 759, 2 U.S.P.Q. 2d (BNA) 2039, 1987 U.S. Dist. LEXIS 3100
CourtDistrict Court, S.D. New York
DecidedApril 22, 1987
Docket85 CIV 4326 (LBS)
StatusPublished
Cited by5 cases

This text of 658 F. Supp. 759 (New York Institute of Technology v. Biosound, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
New York Institute of Technology v. Biosound, Inc., 658 F. Supp. 759, 2 U.S.P.Q. 2d (BNA) 2039, 1987 U.S. Dist. LEXIS 3100 (S.D.N.Y. 1987).

Opinion

SAND, District Judge.

This complex litigation arises from a dispute over intellectual property. Presently pending before the Court is plaintiffs motion to disqualify one of the attorneys serving as defendants’ patent counsel.

Background

In 1977, the plaintiff, New York Institute of Technology (“NYIT”), entered into a Research and Development and License Agreement (“Agreement”) with Boehringer Mannheim GmbH (“Boehringer”), the predecessor in interest of defendant Bio-sound, Inc. (“Biosound”). 1 Pursuant to the Agreement, Boehringer obtained an exclusive worldwide license “to utilize, practice, commercialize and exploit” what the Agreement defines as the “NYIT Process” for ultrasonic body scanning. Agreement § 7.01. While the definition of the “NYIT Process” encompasses techniques and features whether patented or unpatentable, the Agreement states that certain elements of the NYIT Process were disclosed in a United States patent which NYIT owned, as well as in certain patent applications designated in Schedule A of the Agreement. See Agreement § 1.04.

NYIT, as the licensor, was obligated under the Agreement, if Boehringer so requested, to prosecute the designated patent applications to issuance. In addition, the Agreement provides that “NYIT shall keep Boehringer informed as to the filing and prosecution” of the designated items. Agreement § 7.07(b). Specifically, the contract states that “NYIT’s patent counsel shall forward copies of all proposed patent applications and patent office actions to Boehringer’s patent counsel and will consult with Boehringer’s patent counsel as to the form of such patent applications and responses to such patent office action.” Agreement § 7.07(b).

It appears that the patent applications listed in Schedule A of the Agreement were prosecuted to issuance. The record of the course of conduct between the parties reflects that there was indeed consultation between Martin Novack, Esq., the patent attorney who represented NYIT in the patent prosecution, and James M. Durlacher, the attorney who represented the licensee. Although Mr. Durlacher testified in a court-ordered deposition that he performed merely “administrative” tasks in connection with the prosecution of the patents, see Transcript of Deposition of James M. Dur-lacher (“Durlacher Transcript”) at 115, the record indicates that Durlacher’s role was more substantive. See, e.g., Durlacher Transcript at 66-70, 90-95.

*761 After NYIT and Boehringer entered into the Agreement, two of the patents allegedly included within the rubric of the licensed NYIT Process were challenged in a Florida federal court action (the “HRL Litigation”). NYIT and defendant Biosound had a mutual interest in that litigation — to uphold the validity of the challenged patents. Accordingly, both attorney Durlacher — on behalf of the licensee — and attorney Novack — on behalf of the patentee — participated in the proceedings in defense of the patents. Ultimately, the patents at issue in the HRL Litigation were declared invalid. At some point and for reasons which are disputed, Biosound decided to reevaluate its royalty arrangement with NYIT. Thereafter, Biosound reduced the royalty payments and the present action ensued.

The suit was commenced as a contract action but, with the filing of an Amended Answer and counterclaims, was re-cast as a contract/patent action. Claiming, inter alia, that Biosound’s withholding of royalties constitutes a wilful breach of contract, NYIT seeks consequential and punitive damages. In response, defendant Bio-sound asserts that it had a legally sound basis for reducing royalty payments owing under the Agreement. Furthermore, the defendants contend that five patents which are intimately related to the royalty obligations are invalid.

Enmeshed in the thicket of this dispute is the controversy over the role of Mr. Dur-lacher, who now serves as patent co-counsel to the defendants and who, at all relevant times, represented the defendants in connection with the licensing arrangement with NYIT. Plaintiffs motion to disqualify Durlacher is based on two theories. First, NYIT claims that the challenged attorney’s representation of the defendants in this action creates an impermissible appearance of impropriety. Second, plaintiff argues that Durlacher must be disqualified because of his potential role as a witness at the trial. We highlight, as we did in a previous order entered with respect to the motion, that “there is no claim that Dur-lacher’s representation of the defendants implicates Canon 4 of The American Bar Association Code of Professional Responsibility. There is no claim that disqualification is needed to preserve client confidences.” Order, 85 Civ. 4326 (Jan. 27, 1987) [Available on WESTLAW, DCT database].

Discussion

I. The Alleged “Appearance of Impropriety”

Canon 9, on which NYIT relies, provides that “[a] lawyer should avoid even the appearance of impropriety.” The Second Circuit has cautioned, however, that in approaching disqualification motions grounded on Canon 9, courts should take a “restrained” view. Armstrong v. McAlpin, 625 F.2d 433, 446 (2d Cir.1980) (en banc), vacated on other grounds and remanded, 449 U.S. 1106, 101 S.Ct. 911, 66 L.Ed.2d 835 (1981). Indeed, only in “unusual situations” is “the ‘appearance of impropriety’ alone ... sufficient to warrant disqualification.” Id. In the absence of “a threat of taint to the trial, ... possible ethical conflicts surfacing during a litigation are generally better addressed by the ‘comprehensive disciplinary machinery’ of the state and federal bar....” Id. quoting from Bd. of Ed. of N.Y. City v. Nyquist, 590 F.2d 1241, 1246 (2d Cir.1979).

Recognizing the force of this case law, NYIT argues that this is the unusual case which calls for disqualification on the basis of an appearance of impropriety. See Memorandum of Law in Support of Plaintiff’s Motion to Disqualify Defendants’ Counsel at 9. Factually, what underlies this argument is plaintiff’s claim that Dur-lacher “actively participated in the prosecution of the patents which the defendants now seek to have invalidated.” Id. at 1. In addition, plaintiff cites the role Durlacher played in the defense of the patents at issue in the HRL Litigation (which are not the same as those at issue here) as a factor which “add[s] to the appearance of impropriety.” Id. at 12 n. 1. NYIT contends that because Durlacher is in the “unseemly” position of attacking the validity of patents he helped prosecute and defend, he *762 should be disqualified on ethical grounds. Id. at 1.

We do not agree that the alleged appearance of impropriety in this case presents the “unusual” situation in which disqualification on Canon 9 grounds alone is warranted. At all times, Durlacher represented the interests of the licensee under the Agreement.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Stratavest Ltd. v. Rogers
903 F. Supp. 663 (S.D. New York, 1995)
Paramount Communications, Inc. v. Donaghy
858 F. Supp. 391 (S.D. New York, 1994)
de Venezuela v. M/T Trade Resolve
847 F. Supp. 1177 (S.D. New York, 1994)
Complaint of Maritima Aragua, Sa
847 F. Supp. 1177 (S.D. New York, 1994)

Cite This Page — Counsel Stack

Bluebook (online)
658 F. Supp. 759, 2 U.S.P.Q. 2d (BNA) 2039, 1987 U.S. Dist. LEXIS 3100, Counsel Stack Legal Research, https://law.counselstack.com/opinion/new-york-institute-of-technology-v-biosound-inc-nysd-1987.